[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Tt Electronics Plc LSE:TTG London Ordinary Share GB0008711763 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -0.19% 266.00 266.00 268.50 270.00 265.00 267.00 165,675 16:29:48
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 431.8 2.9 0.8 332.5 469

Tt Electronics Share Discussion Threads

Showing 3951 to 3973 of 3975 messages
Chat Pages: 159  158  157  156  155  154  153  152  151  150  149  148  Older
DateSubjectAuthorDiscuss
24/7/2021
11:59
Any recent news on how Virolens trials are going, not seen anything since April 21. Thanks
northener
09/7/2021
18:48
Read a few papers/studies regarding antibodies, either from recovered or vaccine, and it appears that in the elderly they do wane quite noticeably. Ok, antibodies are not the whole picture, memory cells etc. But what I was wondering, is if the gov want to rightly target a cohort, could the virolens machine be set up to detect antibodies? As it seems a far chunk of kit to just look for the virus. No point in vaccinating folk who still have good antibody levels, what with the risk of adverse reactions
games
07/6/2021
20:43
Given its history one would expect it to need substantial good news to break through the 250/260p range. Too many neddies will just be happy to see their money back unless a big juicy carrot dangles in the near future.
boadicea
02/5/2021
12:12
Interestinghttps://www.thenorthernecho.co.uk/news/19271133.chancellor-rishi-sunak-visits-hartlepool-firm-developing-ground-breaking-covid-test/
tinfoil
29/4/2021
05:53
That remains to be seen.
glavey
27/4/2021
20:49
19/04/21. XTEK Ltd's (ASX:XTE) managing director Phillipe Odouard speaks to Proactive soon after signing an agreement with KeyOptions Pty Ltd to exclusively distribute and support Virolens, which is designed to screen for SARS-CoV-2 in around 20-30 seconds, in Australia, New Zealand and the Pacific independent states. The Virolens system is a COVID-19 screening device based on microscopic holographic imaging and artificial intelligence (AI) software technology. 136,000 shares bought after close reckless fools, what do they know?
earwacks
27/4/2021
05:48
3 monkeys.
glavey
25/4/2021
23:15
Where did Glavey go??
tinnerz187
25/4/2021
07:55
Hi earwacks, yes i agree it doesn't matter what other people think. We are all just looking for earnings growth in the end. I don't follow that person on stockopedia, and don't use stockopedia in fact, but again there is always a load of noise out there. I guess that is part of where mispricing comes from. I also agree about the press in general and specifically for the virolens product. I reckon i have learnt something by this situation about how to handle the press. The ft in particular as per my rant a few posts ago i think were disgraceful. Three separate journalists just wrote lazy, judgemental articles. Technology business development (i mean physical technology products not software) is a very very tough world, i know from experience. But if something potentially ticks all the boxes it should 100% be given a chance... whether by the press, vc investors, tech incubators or whatever. Not only because that is where innovation and economic growth come from but also because when things win they win big, and it does happen every now and then. Actually here we have exposure to an interesting new product via an established company which is great.
aringadingding
24/4/2021
09:58
At the end of the day Ari, it doesn't make any difference what people say. I was really surprised when PS on Stockopeia felt he got stung buying into the spike when Sky broke the story on Virolens in September. Really an experienced investor like him should know better. Buy on rumour sell on news. He spikes shares everyday with his stock reporting. Some of his analysis is excellent and pretty open about not understanding some sectors. They must also be aware that although they are not recommending shares obviously they have a big enough following to effect share price movement to some degree particularly with small companies when they write an enthusiastic report and similarly when they dismiss a company sometimes unjustly. I do occasionally feel I can't let posts go unanswered, when they clearly have the wrong end of the stick or simply too lazy to research themselves just spouting media tosh. Also I find it quite disrespectful to the companies and other genuine investors. I can't remember the inventors name of Iabra, but here is a guy already using AI in other products who had the nowse to come up with this idea, and within three months have the first prototype in partnership wih TTG tested in the field. Genuinely offering a solution in a serious crisis. What do the media do? savage them with their own ignorance stupidity. Dyson was asked by the government if he could help out with the manufacture of ventilators.He agreed to do this on a non profit basis in return that his workers should not have to pay uk tax. Media savage him. AZn no profit making vaccine. The EU want to sue for not fulfilling contract on a vaccine they have clearly stated they won't use. Probably they feel they could have profited from this by selling them on. What is a matter with all these loonies?
earwacks
24/4/2021
07:37
Very well said earwacks. It's all about the long term potential for this product in both crisis and everyday healthcare.
aringadingding
24/4/2021
07:18
The MHRA does not issue approvals for COVID-19 tests in the way it does for vaccines, having determined they are effective, but registers medical devices with a certification mark if they meet legal criteria, are safe and are made to the standard specified by the manufacturer for the stated purpose. This is not medicine its a testing device. Histate said trials had indicated the test had 98.1% sensitivity, meaning it returns few false negatives, and 99.7% specificity, meaning few false positives.This is in fact a better result than the one back in September discredited by afore mentioned idiot journalist. "Britain gives the go ahead for Virolens 20 second test.' Those are media headlines not the company headlines. MHRA registration totally legitimises the sale of Virolens in the UK. They seeking similar approval in other countries. They have clearly stated that sales entirely depend on confirmation of interest turning into orders. They satisfactorily completed testing at the Brewery, an events company desperate to reopen within a safe environment in London, like thousands of other businesses and entertainment sports venues around the world. I believe they have now moved on to a London Airport to see how it could operate and help speed up the process of passengers through checks outs. I don't know what on earth you mean when you say 'the purpose for the placing is irrelevant.' One of the most ridiculous statements I have read on any BB.It was quite clearly stated for the reason behind the placing. TTG in no way ramped the product that was entirely down to an Iabra, a statement from the boss at Heathrow, and and over eager journalism hungry for a story. To suggest they suddenly decided to buy an American company on the back of a media story about Virolens is frankly stupid beyond belief. They may have quite sensibly taken advantage of the opportunity that presented itself. Thats what a good business does. To suggest they manufactured a situation like that is quite ludicrous. Virolens is a great British invention that has more potential than any other product on the market to rapidly detect any pathogens being carried by humans or animals after further research. TTG are another very capable British company and I have absolutely no doubt about the integrity of either of them. Finally the boss of Iabra actually apologised for the medias misinterpretation of what he actually said or meant. I don't know if you have ever been interviewed by the media , but I am well aware of media trying to put words into your mouth rather than reporting what you actually say. Its no wonder they are being very much more careful about statements to the press, which is a good thing. In fact the Iabra boss won't speak to media at all now, which is hardly surprising having been ambushed twice at airports. We are great inventors and all the media wants to do is build people up to shoot them down to sell their papers, which is why fewer and fewer people buy their lies. If you don't like these companies thats fine, don't invest. If you are not invested then take your malicious gossip and annoy some other bb please.
earwacks
24/4/2021
05:05
For what they raised is irrelevant. That they 'covid ramped' immediately prior is relevant. "Registration does not represent any form of accreditation, certification or approval by the UK Competent Authority(MHRA)". I prefer the integrity of the FT to your view, sorry
glavey
23/4/2021
10:57
Actually they did not raise money for Virlolens. They got a 5 million government grant to develop it. They did a raise money to buy an American electrical earnings enhancing company. You are wrong about the validity of the accreditation. Keyoptions are in the final stages now. They have signed another partner to distribution deal. You sound just like that idiot journalist from the FT. Do your research properly and stop inventing inaccurate and misinformation. Many thanks
earwacks
23/4/2021
02:25
MRHA Registration does not verify product efficacy or represent any form of accreditation, certification or approval. "Virolens" or "iAbra" are not currently indicated. The 'test centres' seem to be testing the product idea, not the participants. The video doesn't not show a functioning covid test centre. It is just a shows a film set. Read carefully, the information on the websites is telling. It seems one can book a test for all days at any time of day. It seems one has to pay £50 to find out if a booking will be confirmed. Does anyone know of any person who has participated and, if so, their experience? TT have already used this covid related PR to ramp the share price to get a raise away.
glavey
22/4/2021
16:45
Do you mean 'we might get some news soon' or 'there is scheduled to be some news soon'?
aringadingding
22/4/2021
16:24
Nice volume today! News pending
tinnerz187
06/4/2021
16:09
Good spot. Yeah when I heard about mass roll out of weekly testing I got excited but seems to be mostly lateral flow that I have read about for this. But possible that virolens in the UK will be used for international travel. Not sure about workplaces? It would be nice to know, if getting on a plane, that everyone had had a test before getting on the plane (and good for the UK to know that for incoming planes also). Boss of Heathrow was an early advocate i'm sure you'll remember. Boris' announcement yesterday was "watch this space" for intl travel. Beyond that I guess with slow roll vaccinations overseas there is short term hope for overseas sales. The long term applications of holographic technology are extremely interesting, but longer term.
aringadingding
06/4/2021
15:53
Big chunks going through at 230p: 2.6m 1m 800k 861k 16:37 UPDATE: Price has held up well on those sells so clearly buyers happy to pick up slugs there. Map it out. Looks like 230p vs 233p. Will keep a watch tomorrow. All imo DYOR
sphere25
27/3/2021
13:02
Regarding MRHA registration, it’s the same requirement as for any of the Lateral Flow Tests that are being used (Excalibur, Innova etc.). They all quote the sensitivity / specificity figures from 400 clinical samples (150 positive / 250 negative) with different viral loads as required by the MHRA. We saw with Innova that the LFT results in real life situations are a lot worse than their registration details. iAbra were running a live trial in February in The City looking for 400 people and then checking them with PCR tests. I’d be surprised if they went ahead with registration if that hadn’t given at least acceptable results, particularly after the media backlash in September. I see there is an instant test centre already set up in the City where they did the trial and watching the video shows it to be a much quicker/simpler/less painful process than LFT/PCR tests. https://www.histate.co.uk/virolens-test-centres.html They're charging £50 for an individual test but I suspect a corporate bulk buyer could get them for less than half that. The news has added £45mm to the TTG market cap which is negligible compared to the LFT/PCR providers (AVCT have >450mm, ODX>125mm rises since their LFT news). If it doesn't take off, the downside is 25p but if they do get 100mm orders a year, the upside is at least 4 times that - a good tradeoff IMHO.
wjccghcc
27/3/2021
12:30
In the article posted by Glavey, I think that media communications training firm is absolutely right to highlight the risks involved in putting out press releases and thus the value of their training. However, if we step back and think about it, does an exaggeration in a press release warrant a savaging of an innovative start up business? The exaggeration I am referring to is the claim that Bristol University had been involved in the trial design. I can't see any other exaggerations, really, and indeed I note the quoted 96.7% specificity (in September 2020) is now discussed as 99.7% (in March 2021). This is real life, this is business, and people make mistakes, including in press releases, but people should also be allowed to move on from them. There were three separate FT articles at the time. They were often dismissive and personal in their attacks made on an innovative company that should be at the very least respected as a matter of course. Rather than engaging brain and doing research, people in a comfy job in London wrote articles disparaging the work of entrepreneurs because they were based "40 miles north of London", equating all physical technology companies with each other and comparing the situation to Theranos. Have they not heard of Cambridge, which is around 60 miles north of London? In the spirit of forgiveness and moving on I think the FT journalists should also be allowed to learn the lessons and move on. Indeed I should probably move on as well and look forward to the opportunities to deploy the technology. I'm just pointing out that there are multiple parts to the case study.
aringadingding
27/3/2021
09:55
Hi Glavey. The last placing was to purchase earnings enhancing US electronics and design manufacturer Torotel, nothing to do with virolens. Schroder bought 5% of TTG last week having sold back in September. I think the results of the recent tests of Virolens would absolutely be price sensitive information as will forthcoming orders when received. What they absolutely do not want is misrepresentation by the media again, so they have sensibly been more cautious on fuelling the sensationalist interpretations of the press. Naturally a lot depends on the sales of these machines which have brought a great deal of media attention and interest declared by many sectors of commerce eager to to open up business in a safer environment.
earwacks
27/3/2021
06:19
"They have been at pains to stress that there is no guarantee of any financial impact from Virolens." Didn't need an RNS then. hTTps://www.electricairwaves.com/when-the-ft-pulled-a-companys-press-release-to-bits/
glavey
Chat Pages: 159  158  157  156  155  154  153  152  151  150  149  148  Older
ADVFN Advertorial
Your Recent History
LSE
TTG
Tt Electro..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210802 19:49:46